

ESMO PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Singapore
4-5 December 2024

CHAIRS

Rebecca A. Dent, Singapore
Matteo Lambertini, Italy

SPEAKERS

Belinda E. Kiely, Australia
Hee Jeong Kim, Republic of Korea
Icro Meattini, Italy
Soo Chin Lee, Singapore

Lester C. H. Leong, Singapore
Kevin Punie, Belgium
Tira J. Y. Tan, Singapore

LEARNING OBJECTIVES

- To learn about screening, diagnosis and staging of breast cancer
- To learn about genetic testing and management of BRCA carriers
- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care, management of early, locally advanced, and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 4 December 2024

09:00-09:10 10'	Opening and welcome	
10'	Welcome and introduction	Rebecca A. Dent, SG Matteo Lambertini, IT
09:10-09:55 45'	MODULE 1 Imaging	Chair: Matteo Lambertini, IT
30'	Imaging (diagnosis, staging, high-risk breast cancer, Artificial Intelligence)	Lester C. H. Leong, SG
15'	Q&A	All
09:55-10:50 55'	MODULE 2 Biology	Chair: Rebecca A. Dent, SG
25'	New breast cancer classification and new technologies: What's relevant in everyday practice? (including Next Generation Sequencing and ESCAT scale)	Kevin Punie, BE
20'	Use of Genomic Assays in early breast cancer (ie. Oncotype, mammoprint etc..)	Kevin Punie, BE
10'	Q&A	All
10:50-11:20	Coffee break	
11:20-12:55 95'	MODULE 3 HER2+ Breast Cancer	Chair: Matteo Lambertini, IT
25'	Escalation and de-escalation in (neo)-adjuvant systemic therapy: What is proven?	Tira J. Y. Tan, SG
25'	Systemic therapy for HER2+ advanced breast cancer: Now and in future	Matteo Lambertini, IT
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
12:55-13:55	Lunch	
13:55-15:20 85'	MODULE 4 Triple Negative Breast Cancer (TNBC)	Chairs: Tira J. Y. Tan, SG
20'	What is the optimal therapy in stage I, II, III in pCR and non-pCR?	Rebecca A. Dent, SG
20'	Systemic therapy for metastatic TNBC	Tira J. Y. Tan, SG
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
15:20-15:50	Coffee break	
15:50-16:25 35'	MODULE 5 Special patient population	Chair: Matteo Lambertini, IT
25'	Special issues in treatment of elderly patients	Belinda E. Kiely, AU
10'	Q&A	All

16:25-17:55 90'	MODULE 6 Communicating bad news to cancer patients	Chair: Belinda E. Kiely, AU
30'	Communicating bad news to cancer patients	Belinda E. Kiely, AU
10'	Q&A	All
50'	Participants clinical case discussion (5x10')	Faculty
19:00	Networking dinner	

Thursday, 5 December 2024

09:00-10:05 65'	MODULE 7 Local-regional treatment	Chair: Icro Meattini, IT
25'	Surgery: What strategy is safe for breast and axilla?	Hee Jeong Kim, KR
25'	Radiotherapy: How short is enough?	Icro Meattini, IT
15'	Q&A	All
10:05-10:50 45'	MODULE 8 Issues in Advanced Breast Cancer	Chair: Rebecca A. Dent, SG
30'	ER+ Advanced Breast Cancer, 1 st line and beyond (PIK3CA, ESR1 mutations, ADCs, AKT, etc...)	Soo Chin Lee, SG
15'	Q&A	All
10:50-11:20	Coffee break	
11:20-11:55 35'	MODULE 9 BRCA	Chair: Rebecca A. Dent, SG
20'	Genetic counselling/testing and its therapeutic implications	Soo Chin Lee, SG
15'	Q&A	All
11:55-13:10 75'	MODULE 10 Early ER+ Breast Cancer	Chair: Hee Jeong Kim, KR
20'	Pregnancy: Planning for, during and after treatment	Matteo Lambertini, IT
20'	Systemic therapy for adjuvant ER+ and when is ovarian suppression warranted?	Hee Jeong Kim, KR
20'	Best systemic therapy high risk ER+ HER2 negative breast cancer? (choice of chemo, role of CDKi)	Icro Meattini, IT
15'	Q&A	All
13:10-13:15 5'	Closing remarks	Rebecca A. Dent, SG Matteo Lambertini, IT
13:15-14:15	Lunch	

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion